Literature DB >> 18652535

Ethnic differences in the frequency of the cardioprotective C679X PCSK9 mutation in a West African population.

Francine Sirois1, Elias Gbeha, Ambaliou Sanni, Michel Chretien, Damian Labuda, Majambu Mbikay.   

Abstract

PCSK9 is a liver-secreted blood protein that promotes the degradation of low-density lipoprotein receptors, leading to reduced hepatic uptake of plasma cholesterol. Nucleotide variations in its gene have been linked to hypo- and hyper-cholesterolemia. Two nonsense mutations, Y142X and C679X, are associated to lifelong hypocholesterolemia and a remarkable protection against coronary heart disease (CHD) in African Americans. The aim of this study was to determine the frequency of these cardioprotective mutations in West Africans. Subjects (n = 520) from different ethnic groups were recruited in Burkina-Faso, Benin, and Togo. Only the C679X mutation was detected. All carriers were heterozygous. The overall heterozygosity frequency was 3.3%. It varied significantly among ethnic groups, ranging from 0% to 6.9%. The overall high frequency of the cardioprotective C679X mutation in Africa may contribute to the lower incidence of CHD on this continent. The interethnic frequency differences may reflect historical settlement and migration patterns in the region, possibly combined with positive selection for the mutation driven by yet-unknown environmental factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18652535     DOI: 10.1089/gte.2008.0013

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  6 in total

1.  Allelic clustering and ancestry-dependent frequencies of rs6232, rs6234, and rs6235 PCSK1 SNPs in a Northern Ontario population sample.

Authors:  Francine Sirois; Nadine Kaefer; Krista A Currie; Michel Chrétien; Kabwe K Nkongolo; Majambu Mbikay
Journal:  J Community Genet       Date:  2012-02-04

2.  Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained.

Authors:  Paul Lebeau; Khrystyna Platko; Ali A Al-Hashimi; Jae Hyun Byun; Šárka Lhoták; Nicholas Holzapfel; Gabriel Gyulay; Suleiman A Igdoura; David R Cool; Bernardo Trigatti; Nabil G Seidah; Richard C Austin
Journal:  J Biol Chem       Date:  2018-03-28       Impact factor: 5.157

3.  Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children.

Authors:  Charles Arama; Issa Diarra; Bourèma Kouriba; Francine Sirois; Olesya Fedoryak; Mahamadou A Thera; Drissa Coulibaly; Kirsten E Lyke; Christopher V Plowe; Michel Chrétien; Ogobara K Doumbo; Majambu Mbikay
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

4.  Identification of Proteins Interacting with PCSK9 Using a Protoarray Human Protein Microarray.

Authors:  Catherine J Wooten; Sreevidhya T Krishnaji; Quantil M Melendez; Dayami Lopez
Journal:  Int J Biomed Investig       Date:  2019-09-18

5.  Patterns and tempo of PCSK9 pseudogenizations suggest an ancient divergence in mammalian cholesterol homeostasis mechanisms.

Authors:  Barbara van Asch; Luís Filipe Teixeira da Costa
Journal:  Genetica       Date:  2021-01-30       Impact factor: 1.082

Review 6.  The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.

Authors:  Nabil G Seidah
Journal:  Glob Cardiol Sci Pract       Date:  2017-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.